5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study

Van Staa, T. P.; Card, T.; Logan, R. F.; Leufkens, H. G. M.
November 2005
Gut;Nov2005, Vol. 54 Issue 11, p1573
Academic Journal
Background and aims: The objective of this study was to evaluate the risk of colorectal cancer (CRC) in patients taking aminosalicylates (5-ASA) for inflammatory bowel disease (IBD). Methods: The General Practice Research Database (GPRD) which contains the primary care records of five million people in the UK was used to identify users of mesalazine, balsalazide, olsalazine, or sulfasalazine with a history of IBD. In a nested case control analysis, each incident CRC case with any use of a 5-ASA in the six months before the CRC diagnosis was matched by age, sex, and calendar time to six control patients who were also currently using a 5-ASA. Patients were then classified according to regularity of use. The analysis was controlled for body mass index, IBD duration, history of colorectal polyps, use of non-steroidal anti-inflammatory drugs, paracetamol, aspirin, immunosuppressants, oral and rectal glucocorticoids, prior gastrointestinal hospitalisation, recorded colonoscopy, and number of visits to the general practitioner for IBD symptoms in the 6-24 months before diagnosis. Results: The study population included 18 969 patients, of whom 100 had developed CRC during 5-ASA exposure. Most of these cases had a history of ulcerative colitis (76 patients). In the case control analysis, regular users, defined as having six or more 5-ASA prescriptions in the previous 12 months, were found to have a decreased risk of CRC compared with irregular users (crude odds ratio (OR) 0.7 (0.44-1.03); adjusted OR 0.60 (0.38-0.96)). Regular users of sulfasalazine with 6-12 prescriptions before had an adjusted OR of 0.95 (0.22-4.11); with 13-30 prior prescriptions this was 0.41 (0.14-1.20) and with >30 prior prescriptions this was 0.77 (0.37-1.60). For mesalazine users, these values were 1 .13 (0.49- 2.59), 0.30 (0.11-0.83), and 0.31 (0.1 1-0.84), respectively. Conclusion: These results show that regular 5-ASA use is associated with some reduction in the risk of CRC developing in ulcerative colitis.


Related Articles

  • Cytokine and Anti-cytokine Therapies for Inflammatory Bowel Disease. Ogata, Haruhiko; Hibi, Toshifumi // Current Pharmaceutical Design;May2003, Vol. 9 Issue 14, p1107 

    Although the pathogenesis of inflammatory bowel disease (IBD) remains elusive, it appears that there is chronic activation of the immune and inflammatory cascade in genetically susceptible individuals. Current disease management guidelines have therefore focused on the use of anti-inflammatory...

  • Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments. de Mattos, Bruno Rafael Ramos; Garcia, Maellin Pereira Gracindo; Nogueira, Julia Bier; Paiatto, Lisiery Negrini; Albuquerque, Cassia Galdino; Souza, Caique Lopes; Fernandes, Luís Gustavo Romani; Tamashiro, Wirla Maria da Silva Cunha; Simioni, Patricia Ucelli // Mediators of Inflammation;8/3/2015, Vol. 2015, p1 

    Inflammatory bowel diseases (IBD) are characterized by chronic inflammation of the intestinal tract associated with an imbalance of the intestinal microbiota. Crohn’s disease (CD) and ulcerative colitis (UC) are the most widely known types of IBD and have been the focus of attention due...

  • Corticosteroids.  // Reactions Weekly;1/12/2008, Issue 1184, p14 

    The article describes the case of four patients with inflammatory bowel disease and who developed steroid allergy during treatment with corticosteroids. Three patients, a 40-year old man with Crohn's disease, a 53-year old woman and a 39-year old man both with ulcerative colitis, developed...

  • 5-Aminosalicylate Is Not Chemoprophylactic for Colorectal Cancer in IBD: A Population Based Study. Bernstein, Charles N.; Nugent, Zoann; Blanchard, James F. // American Journal of Gastroenterology;Apr2011, Vol. 106 Issue 4, p731 

    OBJECTIVES:We aimed to determine if use of 5-aminosalicylates (5-ASA) was associated with a reduced risk of colorectal cancer (CRC) in people with inflammatory bowel disease (IBD).METHODS:We used the population-based University of Manitoba IBD Epidemiology Database that tracks all health-care...

  • Immune responses triggering colitis and colitis-associated carcinoma. Kesselring, Rebecca; Fichtner-Feigl, Stefan // Langenbeck's Archives of Surgery;Apr2012, Vol. 397 Issue 4, p527 

    Inflammatory bowel diseases compromise of two forms of chronic intestinal inflammatory disorders: Crohn's disease and ulcerative colitis. Both forms of inflammatory bowel disease result from inappropriate inflammatory responses to the intestinal microbiota, but have different underlying immune...

  • Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. Sokol, Harry; Cosnes, Jacques; Chazouilleres, Olivier; Beaugerie, Laurent; Tiret, Emmanuel; Poupon, Raoul; Seksik, Philippe; Ukleja, Andrew // World Journal of Gastroenterology;6/14/2008, Vol. 14 Issue 22, p3497 

    AIM: To investigate the phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD). METHODS: Data from 75 PSC-IBD patients evaluated in our tertiary center between 1963 and 2006 were collected and compared to 150 IBD patients without PSC, matched for sex,...

  • Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? Tilg, Herbert; Danese, Silvio // Gut;Aug2014, Vol. 63 Issue 8, p1204 

    The article presents comments of the author on pathogenesis of ulcerative colitis. Topics discussed include role for intestinal bacteria in Crohn's Disease (CD) for improving of disease during antibiotic therapy, recovery of Faecalibacterium prausnitzii after disease relapse in ulcerative...

  • Current drug therapy in ulcerative colitis. Changtai, X. U.; Shanqu, L. I.; Borong, P. A. N. // Journal of Chinese Clinical Medicine;2009, Vol. 4 Issue 7, p410 

    Ulcerative colitis(UC)and Crohn's disease(CD)are two primary types of inflammatory bowel disease(IBD). UC is an inflammatory destructive disease of the large intestine occurred usually in the rectum and lower part of the colon as well as the entire colon. Drug therapy is a main choice for UC...

  • AGA Reviews the Use of Corticosteroids, Immunomodulators, and Infliximab in IBD. Graham, Lisa // American Family Physician;2/1/2007, Vol. 75 Issue 3, p410 

    The article focuses on the guidance issued by the American Gastroenterological Association (AGA) on the use of corticosteroids, immunomodulators and infliximab in the treatment of inflammatory bowel disease (IBD). Budesonide can be given to patients with mild to moderate IBD but should not be...


Read the Article


Sign out of this library

Other Topics